Seminars in Oncology
Volume 35 , Pages S28-S33 , June 2008

Pharmacokinetics, Metabolites, and Preclinical Safety of Vinflunine

  • Sharon Lobert

      Affiliations

    • University of Mississippi Medical Center, Jackson, MS.
    • ,
  • Christian Puozzo

      Affiliations

    • Institut de Recherche Pierre Fabre, Castres, France.
    • Corresponding Author InformationAddress correspondence to Christian Puozzo, PhD, Oncology Pharmacokinetic Department, Institut de Recherche Pierre Fabre, 2 rue Christian d'Espic, 81106 Castres, France

References 

  1. Fahy J, Duflos A, Ribet J-P, et al. Vinca alkaloids in superacidic media: A method for creating a new family of antitumor derivatives. J Am Chem Soc. 1997;119:8576–8577
  2. Jordan MA, Margolis RL, Himes RH, Wilson L. Identification of a distinct class of vinblastine binding sites on microtubules. J Mol Biol. 1986;187:61–73
  3. Lobert S, Correia JJ. Energetics of vinca alkaloid interactions with tubulin. In:  Johnson M,  Ackers GM editor. Methods in enzymology, energetics of biological macromolecules (Part C,323). New York: Academic Press; 2000;p. 77–103
  4. Lobert S, Frankfurter A, Correia JJ. Binding of vinblastine to phosphocellulose-purified and αβ-class III tubulin: The role of nucleotides and β-tubulin isotypes. Biochemistry. 1995;34:8050–8060
  5. Lobert S, Frankfurter A, Correia JJ. The energetics of vinca alkaloid interactions with tubulin isotypes: Implications for drug efficacy and toxicity. Cell Motil Cytoskeleton. 1998;39:107–121
  6. Lobert S, Ingram JW, Hill BT, Correia JJ. A comparison of thermodynamic parameters for vinorelbine- and vinflunine-induced tubulin self-association by sedimentation velocity. Mol Pharmacol. 1998;53:908–915
  7. Lobert S, Ingram JW, Correia JJ. The thermodynamics of vinca alkaloid-induced tubulin spiral formation. Biophys Chem. 2007;126:50–58
  8. Lobert S, Fahy J, Hill BT, Duflos A, Etievant C, Correia JJ. Vinca alkaloid-induced tubulin spiral formation correlates with cytotoxicity in the leukemic L1210 cell line. Biochemistry. 2000;39:12053–12062
  9. Ngan VK, Bellman K, Panda D, Hill BT, Jordan MA, Wilson L. Novel actions of the antitumor drugs vinflunine and vinorelbine on microtubules. Cancer Res. 2000;60:5045–5051
  10. Okouneva T, Hill BT, Wilson L, Jordan MA. The effects of vinflunine, vinorelbine, and vinblastine on centromere dynamics. Mol Cancer Ther. 2003;2:427–436
  11. Jean-Decoster C, Brichese L, Barret J-M, et al. Vinflunine, a new vinca alkaloid: Cytotoxicity, cellular accumulation and action on the interphasic and mitotic microtubule cytoskeleton of PtK2 cells. Anticancer Drugs. 1999;10:537–543
  12. Ngan VK, Bellman K, Hill BT, Wilson L, Jordan MA. Mechanism of mitotic block and inhibition of cell proliferation by the semisynthetic Vinca alkaloids vinorelbine and its newer derivative vinflunine. Mol Pharmacol. 2001;60:225–232
  13. Hill BT. Vinflunine, a second generation novel vinca alkaloid with a distinctive pharmacological profile, now in clinical development and prospects for future mitotic blockers. Curr Pharm Des. 2001;7:1199–1212
  14. Holwell SE, Hill BT, Bibby MC. Anti-vascular effects of vinflunine in the MAC 15A transplantable adenocarcinoma model. Br J Cancer. 2001;84:290–295
  15. Hill BT, Fiebig H-H, Waud WR, Poupon M-F, Colpaert F, Kruczynski A. Superior in vivo experimental antitumour activity of vinflunine, relative to vinorelbine, in a panel of human tumour xenografts. Eur J Cancer. 1999;35:512–520
  16. Kruczynski A, Colpaert F, Tarayre J-P, Mouillard P, Fahy J, Hill BT. Preclinical in vivo antitumor activity of vinflunine, a novel fluorinated Vinca alkaloid. Cancer Chemother Pharmacol. 1998;41:437–447
  17. Etiévant C, Kruczynski A, Barret J-M, Tait AS, Kavallaris M, Hill BT. Markedly diminished drug resistance-inducing properties of vinflunine (20′,20′-difluoro-3′,4′-dihydrovinorelbine) relative to vinorelbine, identified in murine and human tumour cells in vivo and in vitro. Cancer Chemother Pharmacol. 2001;48:62–70
  18. Roy V, Perez EA. New therapies in the treatment of breast cancer. Semin Oncol. 2006;33(Suppl 9):S3–S8
  19. Macdonald DR. Neurologic complications of chemotherapy. Neurol Clin. 1991;9:955–967
  20. Quasthoff S, Hartung HP. Chemotherapy-induced peripheral neuropathy. J Neurol. 2002;249:9–17
  21. Hussain M, Wozniak AJ, Edelstein MB. Neurotoxicity of antineoplastic agents. Crit Rev Oncol Hematol. 1993;14:61–75
  22. Kaplan RS, Wiernik PH. Neurotoxicity of antineoplastic drugs. Semin Oncol. 1982;9:103–130
  23. Green LS, Donoso JA, Heller-Bettinger IE, Samson FE. Axonal transport disturbances in vincristine-induced peripheral neuropathy. Trans Am Neurol Assoc. 1975;100:195–196
  24. Sahenk Z, Brady ST, Mendell JR. Studies on the pathogenesis of vincristine-induced neuropathy. Muscle Nerve. 1987;10:80–84
  25. Ogawa T, Mimura Y, Isowa K, et al. An antimicrotubule agent, TZT-1027, does not induce neuropathologic alterations which are detected after administration of vincristine or paclitaxel in animal models. Toxicol Lett. 2001;121:97–106
  26. Bennouna J, Fumoleau P, Armand J-P, et al. Phase I and pharmacokinetic study of the new vinca alkaloid vinflunine administered as a 10-min infusion every 3 weeks in patients with advanced solid tumours. Ann Oncol. 2003;14:630–637
  27. Johnson P, Geldart T, Fumoleau P, Pinel M-C, Nguyen L, Judson I. Phase I study of vinflunine administered as a 10-minute infusion on days 1 and 8 every 3 weeks. Invest New Drugs. 2006;24:223–231
  28. Vermoken JB, Stupp R, Nguyen L, et al. Phase I study of i.v. vinflunine given on a weekly schedule in previously untreated patients with advanced solid tumours. [Abstract 887] Proc Am Soc Clin Oncol. 2003;22:221
  29. Zhao X-P, Liu X-Q, Wang Y-S, Wang H, Wang G-J. Pharmacokinetics, tissue distribution and excretion of vinflunine. Eur J Drug Metab Pharmacokinet. 2006;31:59–64
  30. Focan CNJ, Van Heugen J-C, Kreutz F, et al. Vinflunine metabolism and disposition in cancer patients. [Abstract 495] Proc Am Soc Clin Oncol. 2002;21:124a
  31. Zhao X-P, Zhong J, Liu X-Q, Wang G-J. CYP3A4 mediated in vitro metabolism of vinflunine in human liver microsomes. Acta Pharmacol Sin. 2007;28:118–124
  32. Paule B, Saliba F, Gil-Delgado M, et al. Phase I and pharmacokinetic (PK) dose-adjusted study of IV vinflunine (VFL) in cancer patients with liver dysfunction (LD): Pharmacokinetic results. [Abstract 2423] J Clin Oncol. 2007;15(18S):102s
  33. Krzakowski M, Douillard JY, Jassem J, et al. Phase III study of vinflunine versus docetaxel in patients with advanced non-small cell lung cancer previously treated with a platinum containing regimen. J Clin Oncol. 2007;25(18S):387;(abstr 7511)
  34. Bennouna J, Delord JP, Campone M, et al. Vinflunine: a new microtubule inhibitor agent. Clin Cancer Res. 2008;14(6):1625–1632
  35. Talbot DC, Margery J, Dabouis G, et al. Phase II study of vinflunine in malignant pleural mesothelioma. J Clin Oncol. 2007;25(30):4751–4756

 Dr Lobert has received consulting fees from Bristol-Myers Squibb and has received research support from Pierre Fabre Oncologie. Dr Puozzo is an employee of the Institut de Recherche Pierre Fabre, a private pharmaceutical company supporting the development of vinflunine.

PII: S0093-7754(08)00020-1

doi: 10.1053/j.seminoncol.2008.01.007

Seminars in Oncology
Volume 35 , Pages S28-S33 , June 2008

Article Tools

* Image Usage & Resolution